

References

Y-5063

1. Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. *JAMA Oncol.* Jul 13 2017; 3(7): e170580. PMID 28494052
2. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *N Engl J Med.* Oct 15 2015; 373(16): 1541-52. PMID 26465987
3. Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Blood.* Jun 25 2015; 125(26): 4017-23. PMID 25999455
4. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. *J Clin Oncol.* Feb 10 2011; 29(5): 551-65. PMID 21220611
5. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. *J Clin Oncol.* May 10 2010; 28(14): 2339-47. PMID 20385996
6. Bajwa R, Schechter T, Soni S, et al. Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. *Bone Marrow Transplant.* May 2013; 48(5): 661-5. PMID 23128573
7. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *J Clin Oncol.* Apr 20 2006; 24(12): 1917-23. PMID 16622268
8. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. *J Clin Oncol.* Dec 20 2016; 34(36): 4381-4389. PMID 27998223
9. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* May 19 2016; 127(20): 2375-90. PMID 26980727
10. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood.* Jan 01 2006; 107(1): 265-76. PMID 16150940
11. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. *Blood.* Jan 01 2015; 125(1): 22-32. PMID 25499448

12. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. Oct 19 2017; 130(16): 1800-1808. PMID 28774879
13. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol*. Sep 20 2010; 28(27): 4184-90. PMID 20660832
14. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. *Blood*. May 31 2012; 119(22): 5118-25. PMID 22438256
15. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol*. Nov 01 2014; 32(31): 3490-6. PMID 25267740
16. Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant*. Jan 2016; 51(1): 51-7. PMID 26367239
17. Rigacci L, Puccini B, Doderò A, et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. *Ann Hematol*. Jun 2012; 91(6): 931-9. PMID 22245922
18. Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. *Biol Blood Marrow Transplant*. Jan 2010; 16(1): 35-45. PMID 20053330
19. Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. *Bone Marrow Transplant*. Feb 2017; 52(2): 216-221. PMID 27643872
20. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*. Jun 01 1997; 89(11): 3909-18. PMID 9166827
21. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. *Cancer*. Aug 15 2008; 113(4): 791-8. PMID 18615506
22. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. *CA Cancer J Clin*. Nov 12 2016; 66(6): 443-459. PMID 27618563

23. Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. *Oncotarget*. Dec 22 2017; 8(68): 112516-112529. PMID 29348844
24. Federal Register / Vol. 85, No. 104 / Friday, May 29, 2020 / Proposed Rules; KTEX19; Page 175. Federal Register / Vol. 85, No. 104 / Friday, May 29, 2020 / Proposed Rules. Accessed February 18, 2021. <https://www.govinfo.gov/content/pkg/FR-2020-05-29/pdf/2020-10122.pdf>
25. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. *Blood*. Mar 15 1997; 89(6): 2067-78. PMID 9058729
26. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. *J Clin Invest*. Oct 2012; 122(10): 3416-23. PMID 23023712
27. Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. *Blood*. Jan 01 2015; 125(1): 48-55. PMID 25499451
28. Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. *J Clin Oncol*. Apr 20 2019; 37(12): 984-991. PMID 30811293
29. Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. *J Clin Oncol*. Apr 10 2016; 34(11): 1256-69. PMID 26755518
30. Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. *Blood*. Mar 24 2016; 127(12): 1559-63. PMID 26764355
31. Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. *Br J Haematol*. Nov 2018; 183(4): 578-587. PMID 30175400
32. Epperla N, Hamadani M, Cashen AF, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a real world study. *Hematol Oncol*. Dec 2017; 35(4): 528-535. PMID 28066928
33. Robinson SP, Boumendil A, Finel H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. *Bone Marrow Transplant*. May 2018; 53(5): 617-624. PMID 29335632
34. National Comprehensive Cancer Network (NCCN). Acute Lymphoblastic Leukemia. Version 2.2020. 2020 Oct 23; https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf. Accessed February 18, 2021.

35. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant.* Apr 2019; 25(4): 625-638. PMID 30592986
36. National Cancer Institute. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017 Nov 27; https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed February 18, 2021.
37. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med.* Feb 01 2018; 378(5): 439-448. PMID 29385370
38. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci Transl Med.* Sep 02 2015; 7(303): 303ra139. PMID 26333935
39. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. *Crit Care Med.* Feb 2017; 45(2): e124-e131. PMID 27632680
40. National Comprehensive Cancer Network (NCCN). B-Cell Lymphomas. Version 2.2021. Feb 16; <https://www.nccn.org/professionals/physician/gls/pdf/b-cell.pdf>. Accessed February 19, 2021.
41. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol.* Feb 10 2007; 25(5): 579-86. PMID 17242396
42. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* Sep 20 2014; 32(27): 3059-68. PMID 25113753
43. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med.* Jan 03 2019; 380(1): 45-56. PMID 30501490
44. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol.* Jan 2019; 20(1): 31-42. PMID 30518502
45. Kite Pharma Inc. Prescribing Label: Yescarta (axicabtagene ciloleucel) suspension for intravenous infusion. 2017; <https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapy/Products/ApprovedProducts/UCM581226.pdf>. Accessed February 18, 2021.

46. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. Dec 28 2017; 377(26): 2531-2544. PMID 29226797
47. Novartis Pharmaceuticals. Prescribing Label: Kymriah (tisagenlecleucel) suspension for intravenous infusion. 2018; <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kymriah.pdf>. Accessed February 18, 2021.
48. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med*. Apr 02 2020; 382(14): 1331-1342. PMID 32242358
49. Tecartus (brexucabtagene autoleucel) suspension for intravenous infusion. Prescribing label. Accessed on February 18, 2021. <https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf>
50. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet*. Sep 19 2020; 396(10254): 839-852. PMID 32888407
51. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. Jul 10 2014; 124(2): 188-95. PMID 24876563
52. Prescribing label for Breyanzi (lisocabtagene maraleucel) suspension for intravenous infusion. Accessed on February 18, 2021. Available at https://packageinserts.bms.com/pi/pi_breyanzi.pdf
53. Centers for Medicare & Medicaid Services (CMS). Proposed Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N). 2017 Feb 15; <https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=291>. Accessed February 18, 2021.